- Home
- FT vs ACIU Comparison
FT vs ACIU Comparison
Compare FT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- ACIU
- Stock Information
- Founded
- FT 1988
- ACIU 2003
- Country
- FT United States
- ACIU Switzerland
- Employees
- FT N/A
- ACIU N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- ACIU Health Care
- Exchange
- FT Nasdaq
- ACIU Nasdaq
- Market Cap
- FT 187.3M
- ACIU 173.7M
- IPO Year
- FT N/A
- ACIU 2016
- Fundamental
- Price
- FT $7.50
- ACIU $1.57
- Analyst Decision
- FT
- ACIU Strong Buy
- Analyst Count
- FT 0
- ACIU 2
- Target Price
- FT N/A
- ACIU $10.00
- AVG Volume (30 Days)
- FT 63.0K
- ACIU 134.4K
- Earning Date
- FT 01-01-0001
- ACIU 04-30-2025
- Dividend Yield
- FT 7.85%
- ACIU N/A
- EPS Growth
- FT N/A
- ACIU N/A
- EPS
- FT N/A
- ACIU N/A
- Revenue
- FT N/A
- ACIU $32,014,254.00
- Revenue This Year
- FT N/A
- ACIU N/A
- Revenue Next Year
- FT N/A
- ACIU $676.94
- P/E Ratio
- FT N/A
- ACIU N/A
- Revenue Growth
- FT N/A
- ACIU 91.20
- 52 Week Low
- FT $5.97
- ACIU $1.43
- 52 Week High
- FT $7.23
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- FT 60.98
- ACIU 38.57
- Support Level
- FT $7.41
- ACIU $1.55
- Resistance Level
- FT $7.48
- ACIU $1.78
- Average True Range (ATR)
- FT 0.08
- ACIU 0.11
- MACD
- FT 0.02
- ACIU 0.02
- Stochastic Oscillator
- FT 100.00
- ACIU 8.33
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.